Home › Metastatic Cancer › Nebraska › Omaha
Metastatic Cancer clinical trials in Omaha, NE
14 studies for Metastatic Cancer are looking for participants at sites in and around Omaha (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RecruitingPhase 2
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingPhase 3
- University of Nebraska Medical Center, Omaha
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RecruitingPhase 2/3
- University of Nebraska Medical Center, Omaha
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
RecruitingPhase 3
- Nebraska Methodist Hospital, Omaha
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RecruitingPhase 2/3
- Nebraska Medicine, Omaha
- Nebraska Medicine - Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
RecruitingPhase 3
- Research Site, Omaha
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
- Nebraska Cancer Specialists, Omaha
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RecruitingPhase 3
- Nebraska Cancer Specialists, Omaha
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
RecruitingPhase 3
- Nebraska Methodist Hospital, Omaha
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
RecruitingPhase 1
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Nebraska Cancer Specialists, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Omaha
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- Nebraska Cancer Specialists (NCS), Omaha
Metastatic Cancer trials in other cities
- Houston, TX100 studies
- New York City, NY93 studies
- Nashville, TN69 studies
- Boston, MA61 studies
- Los Angeles, CA57 studies
- Arlington, VA52 studies
- St. Louis, MO52 studies
- San Antonio, TX44 studies
- Washington, DC44 studies
- Dallas, TX44 studies
- Philadelphia, PA42 studies
- Chicago, IL42 studies
Other studies in Omaha
- Prostate Cancer29 studies
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer23 studies
- Cancer (all types)19 studies
- Colorectal Cancer18 studies
- Multiple Myeloma17 studies
- Ovarian Cancer15 studies
- Pancreatic Cancer15 studies
- Head and Neck Squamous Cell Carcinoma15 studies
- Non-Hodgkin Lymphoma14 studies
- Lung Cancer13 studies
- Kidney Cancer (Renal Cell Carcinoma)12 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.